UPDATE: Regenicin, Inc. (RGIN.OB) Announces Dismissal of Lawsuit
09 Junho 2011 - 2:17PM
Marketwired
Regenicin, Inc. (OTCBB: RGIN) announced today that an arrangement
has been reached between the Company and its former president, Mr.
Joseph Connell, to dismiss the Company and members of its board of
directors from the lawsuit he brought, now pending in the US
District Court for the Southern District of New York. The Company
in turn has agreed to dismiss its current action against Mr.
Connell pending in the United States District Court for the
District of Nevada. The New York action will thus continue between
Mr. Connell and Mr. McCoy only.
Reflecting on these pending dismissals, Mr. McCoy commented:
"This matter is, and has always been, between Mr. Connell and
myself, so I'm very pleased to have it formally resolved for our
Company, our Board and all our Shareholders. Going forward, this
allows us to more efficiently take the actions we need to take to
make the company a success and reach our joint goals."
About Regenicin, Inc.
Regenicin, Inc. is a biotechnology company with corporate
headquarters in Little Falls, New Jersey. The Company specializes
in the development of regenerative cell therapies to restore the
health of damaged tissues and organs.
Safe Harbor This press release contains certain forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, which are intended to be covered by the safe harbors
created thereby. Investors are cautioned that all forward-looking
statements involve risks and uncertainties, including, without
limitation, the future press releases of Regenicin, Inc.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Randall McCoy Email Contact
Regenicin (CE) (USOTC:RGIN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Regenicin (CE) (USOTC:RGIN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre Regenicin Inc (CE) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Regenicin, Inc.